More detail is needed for updating clinical guidelines.

@article{Garca2016MoreDI,
  title={More detail is needed for updating clinical guidelines.},
  author={Laura Mart{\'i}nez Garc{\'i}a and Hector Pardo-Hernandez and Pablo Alonso-Coello},
  journal={Kidney international},
  year={2016},
  volume={90 3},
  pages={707-8}
}
2. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122:322–328. 3. Jhaveri KD, Sakhiya V, Fishbane S. Nephrotoxicity of the BRAF inhibitors vermurafenib anddabrafenib. JAMA Oncol. 2015;1:1133–1134. 4. Shirali A, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death (PD)-1 inhibitor therapy in lung cancer patients [e-pub ahead of print]. Am J Kidney Dis. http://dx.doi.org/ 10.1053/j.ajkd… CONTINUE READING